October 12, 2017 4:54pm

BTX prices $25 M offering at $2.60 and is trading at $2.63 down -4.03% (-$0.11)


BTX intends to sell 9.515 M shares of its common stock in an underwritten public offering.


BioTime intends to grant the underwriters a 30-day option to purchase up to an aggregate of an additional 15% of the shares of its common stock offered in the public offering to cover over-allotments, if any. The offering is subject to market, regulatory and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.



Raymond James & Associates, Inc. will act as the sole book-running manager for the offering.